Anti-IgSF4 antibody and utilization of the same
View Patent ↗It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.
1. An isolated antibody having specific binding property against IgSF4, which comprises:
a heavy chain variable region having CDR containing the amino acid sequences of SEQ ID NO.:58-60, and;
a light chain variable region having CDR containing the amino acid sequences of SEQ ID NO.:62-64.
2. The isolated antibody according to claim 1 , which is a human antibody or a humanized antibody.
3. The isolated antibody according to claim 1 , which is IgG, Fab, Fab′, F(ab′) 2 , cFv, or dsFv antibody.
4. A therapeutic agent for cancer comprising an antibody as claimed in claim 1 as an active ingredient.
5. A reagent comprising an antibody as claimed in claim 1 , which is used for examination of liver cancer, examination of adult T cell leukemia, study of liver cancer, or study of adult T cell leukemia.
6. The isolated antibody according to claim 1 , which comprises:
a heavy chain variable region and a light chain variable region in a combination of a heavy chain variable region having CDR consisting of CDR1 of SEQ ID NO.:58, CDR2 of SEQ ID NO.:59, and CDR3 of SEQ ID NO.:60, and a light chain variable region having CDR consisting of CDR1 of SEQ ID NO.:62, CDR2 of SEQ ID NO.:63, and CDR3 of SEQ ID NO.:64.